MBRX
Income statement / Annual
Last year (2023), Moleculin Biotech, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Moleculin Biotech, Inc.'s net income was -$29.77 M.
See Moleculin Biotech, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$127,000.00 |
$222,000.00 |
$260,000.00 |
$285,000.00 |
$185,000.00 |
$68,000.00 |
$18,000.00 |
$6,162.00 |
$0.00 |
| Gross Profit |
-$127,000.00 |
-$222,000.00 |
-$260,000.00 |
-$285,000.00 |
-$185,000.00 |
-$68,000.00 |
-$18,000.00 |
-$6,162.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$19.49 M
|
$18.97 M
|
$14.42 M
|
$12.76 M
|
$11.01 M
|
$9.73 M
|
$4.55 M
|
$1.50 M
|
$260,417.00
|
| General & Administrative
Expenses |
$10.02 M
|
$11.67 M
|
$8.39 M
|
$6.79 M
|
$6.31 M
|
$5.30 M
|
$4.09 M
|
$2.38 M
|
$1.15 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$668,934.00
|
| Selling, General &
Administrative Expenses |
$10.02 M
|
$11.67 M
|
$8.39 M
|
$6.79 M
|
$6.31 M
|
$5.30 M
|
$4.09 M
|
$2.38 M
|
$477,810.00
|
| Other Expenses |
$127,000.00 |
$40,000.00 |
$164,000.00 |
$200,000.00 |
$199,000.00 |
-$40,000.00 |
$18,000.00 |
$6,162.00 |
$0.00 |
| Operating Expenses |
$29.63 M |
$30.64 M |
$22.97 M |
$19.74 M |
$17.52 M |
$15.03 M |
$8.65 M |
$3.88 M |
$738,228.00 |
| Cost And Expenses |
$29.63 M |
$30.64 M |
$22.97 M |
$19.74 M |
$17.52 M |
$15.03 M |
$8.65 M |
$3.88 M |
$738,228.00 |
| Interest Income |
$1.37 M |
$240,000.00 |
$306,000.00 |
$13,000.00 |
$13,000.00 |
$0.00 |
$0.00 |
$0.00 |
$24,317.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$43,214.00 |
$0.00 |
| Depreciation &
Amortization |
$127,000.00
|
$222,000.00
|
$260,000.00
|
$285,000.00
|
$185,000.00
|
$68,000.00
|
$18,000.00
|
$6,162.00
|
$1.77 M
|
| EBITDA |
-$29.50 M
|
-$30.51 M
|
-$22.80 M
|
-$19.54 M
|
-$13.25 M
|
-$14.96 M
|
-$8.64 M
|
-$3.88 M
|
$0.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$138,000.00
|
$1.62 M
|
$7.07 M
|
$2.39 M
|
$4.09 M
|
$3.15 M
|
-$1.15 M
|
-$43,361.00
|
-$10,130.00
|
| Income Before Tax |
-$29.77 M |
-$29.03 M |
-$15.89 M |
-$17.36 M |
-$13.43 M |
-$11.88 M |
-$9.81 M |
-$3.93 M |
-$748,360.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.62 M |
-$7.03 M |
-$2.36 M |
-$229,000.00 |
$3.15 M |
$1.15 M |
$0.00 |
-$1.77 M |
| Net Income |
-$29.77 M |
-$27.41 M |
-$8.86 M |
-$15.00 M |
-$13.21 M |
-$11.88 M |
-$9.81 M |
-$3.93 M |
-$748,360.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-15.07 |
-14.37 |
-4.94 |
-22.85 |
-29.18 |
-41.26 |
-47.52 |
-35.96 |
-11.88 |
| EPS Diluted |
-15.07 |
-14.37 |
-4.94 |
-22.85 |
-29.18 |
-41.26 |
-47.52 |
-35.96 |
-11.83 |
| Weighted Average Shares
Out |
$1.98 M
|
$1.91 M
|
$1.79 M
|
$656,377.00
|
$452,460.00
|
$287,824.00
|
$206,324.00
|
$109,194.00
|
$63,000.00
|
| Weighted Average Shares
Out Diluted |
$1.98 M
|
$1.91 M
|
$1.79 M
|
$656,377.00
|
$452,460.00
|
$287,824.00
|
$206,324.00
|
$109,194.00
|
$63,242.00
|
| Link |
|
|
|
|
|
|
|
|
|
